Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

about

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Item

http://www.wikidata.org/entity/Q57052257

description

wetenschappelijk artikel

@nl

name

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@en

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@nl

type

Item

label

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@en

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@nl

prefLabel

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@en

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@nl

P1476

Team Management of Skin Rash A ...... tor-Tyrosine Kinase Inhibitors

@en

P2093

Fumiko Imamichi

http://www.w3.org/2001/XMLSchema#string

Kana Hatakenaka

http://www.w3.org/2001/XMLSchema#string

Katsuhiro Masago

http://www.w3.org/2001/XMLSchema#string

Kiyomi Fujitomi

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Katakami

http://www.w3.org/2001/XMLSchema#string

Noriko Ariga

http://www.w3.org/2001/XMLSchema#string

Shiro Fujita

http://www.w3.org/2001/XMLSchema#string

Yoko Fukumine

http://www.w3.org/2001/XMLSchema#string

Yoshio Masuda

http://www.w3.org/2001/XMLSchema#string

P2860

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Erlotinib in previously treated non-small-cell lung cancer

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.

The Skindex instruments to measure the effects of skin disease on quality of life

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.

P304

430-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/APJON.APJON_33_18

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P698

30271827

http://www.w3.org/2001/XMLSchema#string

P932

6103195

http://www.w3.org/2001/XMLSchema#string